RECRUITINGINTERVENTIONAL

Metabolomics Analysis According to the Retinal Nerve Fiber Layer in Patients With NOHL Mutations (MétabOCT)

Metabolomics Analysis According to the Thickness of the Retinal Nerve Fiber Layer in Patients With NOHL Mutations

About This Trial

Leber hereditary optic neuropathy (LHON), due to mitochondrial DNA (mtDNA) mutations, is responsible for profound visual impairment. However, there is evidence that optic nerve damage begins before vision declines. There is no biomarker to determine when optic nerve damage begins before visual acuity decline occurs. We hope that the analysis of metabolomics will reveal specific metabolomic profiles and different vitamin B3 and B9 levels depending on whether there are OCT signs of optic nerve damage in healthy patients with mtDNA mutations suggestive of LHON (11778, 3460 or 14484). The existence of an increase in the thickness of the optic fiber layer, whose normal values are well established, constitutes such a sign in favor of optic nerve damage.

Who May Be Eligible (Plain English)

Who May Qualify: - Patient carrying an mtDNA mutation suggestive of NOHL (11778, 3460 or 14484) with normal visual acuity and who has never had optic neuropathy, or Patient not carrying an mtDNA mutation suggestive of NOHL (11778, 3460 or 14484) with normal visual acuity and who has never had optic neuropathy; - Patient agreeing to undergo an OCT; - Patient agreeing to sign the willing to sign a consent form; - Patient affiliated to French social protection (Primary Health Insurance Fund, CMU, etc.) or European social protection. Who Should NOT Join This Trial: - Patient with or having had optic neuropathy regardless of its etiology - Patient with glaucoma regardless of its etiology; - Patient not wanting to undergo OCT; - Patient not wanting to sign the willing to sign a consent form; - Patient not affiliated with French social protection (Primary Health Insurance Fund, CMU, etc.) or European. - Patients less than 18 years old or over 60 years old - Pregnant patient Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Patient carrying an mtDNA mutation suggestive of NOHL (11778, 3460 or 14484) with normal visual acuity and who has never had optic neuropathy, or Patient not carrying an mtDNA mutation suggestive of NOHL (11778, 3460 or 14484) with normal visual acuity and who has never had optic neuropathy; * Patient agreeing to undergo an OCT; * Patient agreeing to sign the informed consent; * Patient affiliated to French social protection (Primary Health Insurance Fund, CMU, etc.) or European social protection. Exclusion Criteria: * Patient with or having had optic neuropathy regardless of its etiology * Patient with glaucoma regardless of its etiology; * Patient not wanting to undergo OCT; * Patient not wanting to sign the informed consent; * Patient not affiliated with French social protection (Primary Health Insurance Fund, CMU, etc.) or European. * Patients less than 18 years old or over 60 years old * Pregnant patient

Treatments Being Tested

DIAGNOSTIC_TEST

Optical coherent tomography

We compare the metabolomics profile of healthy patients based on the OCT appearance of the optic disc and RNFL

Locations (1)

HEGP

Paris, Paris, France